SmartLab 2.0 in cardiovascular prevention of atherogenic dyslipidemia

SmartLab 2.0 is an innovative concept of multidisciplinary collaboration between the clinical laboratory and the diabetes day unit that was born with the aim of identifying patients at high cardiovascular risk who require priority attention, such as patients with atherogenic dyslipidemia, in order t...

Full description

Saved in:
Bibliographic Details
Published in:Clínica e investigación en arteriosclerosis (Internet, English ed.) English ed.), 2023-05, Vol.35 (3), p.123-128
Main Authors: Galván Toribio, Raquel, Arrobas Velilla, Teresa, Morales Porillo, Cristóbal, Rico, Miguel Ángel, Martínez Quesada, Mar, León Justel, Antonio
Format: Article
Language:English
Subjects:
Alerta temprana
Atherogenic dyslipidemia
Cardiovascular prevention
Diabetes
Dislipemia aterogénica
Early warning
Prevención cardiovascular
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:SmartLab 2.0 is an innovative concept of multidisciplinary collaboration between the clinical laboratory and the diabetes day unit that was born with the aim of identifying patients at high cardiovascular risk who require priority attention, such as patients with atherogenic dyslipidemia, in order to create a cardiovascular prevention strategy. Implementation in the Laboratory Information System (LIS) of an automated biochemical algorithm for the identification of patients with atherogenic dyslipidemia in routine analyses and priority referral to the diabetes day unit. The algorithm designed in the SIL was: HBA1c>9.3+TG>150mg/dl+HDLc9.3 were referred to the diabetes day hospital. Reinforcement of cardiovascular prevention is necessary at all levels. The clinical laboratory should play a fundamental role in the diagnosis of dyslipidemias. Early detection of patients at high cardiovascular risk is essential and collaboration between the different clinical units is fundamental to guarantee patient safety. El SmartLab 2.0 es un concepto innovador de colaboración multidisciplinar entre el laboratorio clínico y la unidad de día de diabetes que nace con el objetivo de identificar a pacientes de alto riesgo cardiovascular que requieran una atención prioritaria, como son los pacientes que presentan dislipemia aterogénica, con el fin de crear una estrategia de prevención cardiovascular. Implementación en el sistema informático de laboratorio (SIL) de un algoritmo bioquímico automatizado para la identificación en analíticas de rutina de pacientes con dislipemia aterogénica y derivación prioritaria a la unidad de día de diabetes. Se diseñó en el SIL el algoritmo: HBA1c>9,3+TG>150mg/dl+cHDL
ISSN:2529-9123
2529-9123
DOI:10.1016/j.artere.2023.05.009